Plasma Vascular Endothelial Growth Factor‐A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
Plasma VEGF-A levels were identified as a significant biomarker for early PD in individuals with HCC receiving Atezo/Bev therapy.
Authors
- Yasuhiko Nakao (ORCID: https://orcid.org/0000-0002-9353-2780)
- Masafumi Haraguchi (ORCID: https://orcid.org/0000-0002-8564-0490)
- Hisamitsu Miyaaki (ORCID: https://orcid.org/0000-0002-8067-4376)
- Tatsuki Ichikawa (ORCID: https://orcid.org/0000-0001-9752-3278)
- Akane Shimakura
- Yasuko Kanda
- Kazuhiko Nakao (ORCID: https://orcid.org/0000-0002-7860-7123)
- Masanori Fukushima (ORCID: https://orcid.org/0000-0001-8594-0066)
- Ryu Sasaki (ORCID: https://orcid.org/0000-0002-0001-7377)
- Kazuaki Tajima
- Eisuke Ozawa (ORCID: https://orcid.org/0000-0002-2226-781X)
- Satoshi Miuma (ORCID: https://orcid.org/0000-0003-2639-7299)
- Satoshi Matsuo
- Kosuke Takahashi (ORCID: https://orcid.org/0000-0001-9690-7472)
Institutions
- Sasebo City General Hospital (JP)
- Nagasaki Medical Center (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1111/hepr.70102
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00